Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305190 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL939477 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL7330819 | 0.91 | CTSK (0.44) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL15582702 | 0.87 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL1688920 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3735030 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL12973256 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3733285 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16000767 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16343552 | 0.86 | CTSK (0.46) | CTSSCTSKCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | claimed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| CN-112778162-B | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | claimed |
| CN-112778162-A | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | NAUTILUS SUBSIDIARY INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-1268469-A1 | N-(HETEROCYCLYL)BENZENE OR PYRIDINE SULPHONAMIDES AS ANTITHROMBOTIC AGENTS AND ANTICOAGULANTS | SANOFI-SYNTHELABO (FR) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070736-A1 | N-(HETEROCYCLYL)BENZENE OR PYRIDINE SULPHONAMIDES AS ANTITHROMBOTIC AGENTS AND ANTICOAGULANTS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
| EP-0946517-A1 | N-(IMIDAZOLYLBUTYL) BENZENESULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SYNTHELABO (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022443-A1 | N-(IMIDAZOLYLBUTYL) BENZENESULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SYNTHELABO (FR) | 1998-05-28 | — | — | WO | disclosed |
| US-5665598-A | Synthesis of chiral N-protected-α-substituted-glycine free acids by zinc-mediated addition of organic halide to glycine cation equivalent | G. D. SEARLE & CO. (US) | 1997-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | CTSS 3724/4885CTSK 4174/4885CTSL 3849/4885 |
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | SPPL2B, SNAP29, SPPL2A | CTSS 1949/4885CTSK 2951/4885CTSL 124/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSS 7/4885CTSK 50/4885CTSL 3/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | CTSS 3724/4885CTSK 4174/4885CTSL 3849/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | CTSS 977/4885CTSK 2216/4885CTSL 473/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | CTSS 3724/4885CTSK 4174/4885CTSL 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.